The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis

With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism

Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.

The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies and genome editing therapies. The study also features an elaborate discussion on the future potential of this evolving market. In addition to other elements, the study includes:
 A detailed review of the overall landscape of gene therapies and genome editing therapies.
 A discussion on the various types of viral and non-viral vectors.
 A world map representation, depicting the most active geographies, and a bull’s eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy.
 A discussion on the regulatory landscape related to gene therapies across various geographies.
 Detailed profiles of marketed and phase II/III and gene therapies.
 An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development.
 A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies.
 An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016.
 An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019.

Leave a Reply

Your email address will not be published. Required fields are marked *

The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis

An exponential increase in development efforts related to wearable medical devices and implants, has fueled a corresponding rise in demand for safe, compact, light-weight and high energy density batteries with longer life span

Roots Analysis has announced the addition of “Medical Device Batteries: Focus on Implants and Wearable Medical Devices – Market Distribution by Battery Chemistry (Lithium, Zinc Air, Nickel and Others), Rechargeability (Rechargeable and Non-Rechargeable), Application (Hearing Aids, Patient Monitoring Devices, Drug Delivery Devices, Cardiovascular Medical Devices and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030” report to its list of offerings.

Battery-operated medical devices, such as cochlear implants, defibrillators, insulin pumps and pacemakers, have redefined 21st century healthcare, adding to the user convenience factor and offering profitable value propositions for developers. Battery technologies have simultaneously evolved, with modern power-storage cells having improved safety features and the potential to be used for longer durations.

To order this 190+ page report, which features 60+ figures and 90+ tables, please visit this –
https://www.rootsanalysis.com/reports/medical-device-batteries-market.html

Key Market Insights

More than 930 batteries, designed for use in medical devices, are currently available / under development
More than 75% of the aforementioned batteries that are intended for implants and wearable medical devices, have lithium based chemistries. The majority of batteries captured in the report (62%) are intended for hearing aids; this is followed by those used in patient monitoring devices (17%) and drug delivery devices (12%).

Leave a Reply

Your email address will not be published. Required fields are marked *